AR114544A1 - Proteínas de unión multiespecíficas que unen a bcma, nkg2d y cd16, y métodos de uso - Google Patents

Proteínas de unión multiespecíficas que unen a bcma, nkg2d y cd16, y métodos de uso

Info

Publication number
AR114544A1
AR114544A1 ARP190102253A ARP190102253A AR114544A1 AR 114544 A1 AR114544 A1 AR 114544A1 AR P190102253 A ARP190102253 A AR P190102253A AR P190102253 A ARP190102253 A AR P190102253A AR 114544 A1 AR114544 A1 AR 114544A1
Authority
AR
Argentina
Prior art keywords
bcma
antigen
binds
bind
nkg2d
Prior art date
Application number
ARP190102253A
Other languages
English (en)
Inventor
Bianka Prinz
Bradley M Lunde
Nicolai Wagtmann
William Haney
Asya Grinberg
Ann F Cheung
Gregory P Chang
Mitchell Bigelow
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of AR114544A1 publication Critical patent/AR114544A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Proteínas de unión multiespecíficas que se unen y destruyen las células cancerosas humanas que expresan el antígeno de maduración de células B (BCMA), así como las composiciones farmacéuticas y los métodos terapéuticos útiles para el tratamiento del cáncer que expresa BCMA. También proteínas de unión multiespecíficas que se unen y destruyen las células cancerosas humanas que expresan BCMA, y exhiben una alta potencia y una lisis máxima de células diana en comparación con los anticuerpos monoclonales anti-BCMA. Reivindicación 1: Una proteína caracterizada porque comprende: (a) un primer sitio de unión a antígeno que comprende un fragmento variable de cadena simple (scFv) que se une a NKG2D; (b) un segundo sitio de unión a antígeno que se une al antígeno de maduración de células B (BCMA); y (c) un dominio Fc de anticuerpo o una porción del mismo suficiente para unirse a CD16, o un tercer sitio de unión a antígeno que se une a CD16.
ARP190102253A 2018-08-08 2019-08-08 Proteínas de unión multiespecíficas que unen a bcma, nkg2d y cd16, y métodos de uso AR114544A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862716207P 2018-08-08 2018-08-08

Publications (1)

Publication Number Publication Date
AR114544A1 true AR114544A1 (es) 2020-09-16

Family

ID=69413838

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102253A AR114544A1 (es) 2018-08-08 2019-08-08 Proteínas de unión multiespecíficas que unen a bcma, nkg2d y cd16, y métodos de uso

Country Status (19)

Country Link
US (2) US20210317223A1 (es)
EP (1) EP3833392A4 (es)
JP (1) JP7515459B2 (es)
KR (1) KR20210043602A (es)
CN (1) CN112823022A (es)
AR (1) AR114544A1 (es)
AU (1) AU2019318083A1 (es)
BR (1) BR112021002072A2 (es)
CA (1) CA3108427A1 (es)
CL (1) CL2021000316A1 (es)
CO (1) CO2021001410A2 (es)
EA (1) EA202190468A1 (es)
IL (1) IL280512A (es)
MA (1) MA53293A (es)
MX (1) MX2021001524A (es)
PE (1) PE20211860A1 (es)
SG (1) SG11202100883SA (es)
TW (1) TW202019479A (es)
WO (1) WO2020033630A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US20230364230A1 (en) * 2020-09-11 2023-11-16 Engmab Sàrl Combination therapy for cancer
CN117881702A (zh) * 2021-08-03 2024-04-12 山东先声生物制药有限公司 一种cd16抗体及其应用
WO2023107956A1 (en) * 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2274008T3 (da) 2008-03-27 2014-05-12 Zymogenetics Inc Sammensætninger og fremgangsmåder til hæmning af PDGFRBETA og VEGF-A
CA2761233A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2817015A1 (en) * 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
US20140377269A1 (en) * 2012-12-19 2014-12-25 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
SG11201704727WA (en) 2014-12-12 2017-07-28 Bluebird Bio Inc Bcma chimeric antigen receptors
JP6744313B2 (ja) 2015-01-02 2020-08-26 ダイアックス コーポレーション 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
CN107530424A (zh) * 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
CN115160438A (zh) * 2015-04-06 2022-10-11 苏伯多曼有限责任公司 含有从头结合结构域的多肽及其用途
HUE048939T2 (hu) * 2015-08-03 2020-09-28 Engmab Sarl Human B sejt érési antigén elleni monoklonális antitestek (BCMA)
MA53750A (fr) 2015-08-17 2021-09-15 Janssen Pharmaceutica Nv Anticorps anti-bcma, molécules de liaison d'antigène bispécifiques qui se lient au bcma et cd3 et leurs utilisations
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CA3044593A1 (en) * 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
BR112019016424A2 (pt) * 2017-02-10 2020-04-07 Dragonfly Therapeutics Inc proteínas de ligação a bcma, nkg2d e cd16

Also Published As

Publication number Publication date
WO2020033630A1 (en) 2020-02-13
EP3833392A1 (en) 2021-06-16
TW202019479A (zh) 2020-06-01
CO2021001410A2 (es) 2021-05-10
KR20210043602A (ko) 2021-04-21
JP2021533169A (ja) 2021-12-02
JP7515459B2 (ja) 2024-07-12
CN112823022A (zh) 2021-05-18
US20210317223A1 (en) 2021-10-14
MX2021001524A (es) 2021-04-19
SG11202100883SA (en) 2021-02-25
EA202190468A1 (ru) 2021-07-06
BR112021002072A2 (pt) 2021-06-01
CL2021000316A1 (es) 2021-07-30
PE20211860A1 (es) 2021-09-21
EP3833392A4 (en) 2022-05-18
CA3108427A1 (en) 2020-02-13
AU2019318083A1 (en) 2021-02-25
US20220089760A1 (en) 2022-03-24
MA53293A (fr) 2021-11-17
IL280512A (en) 2021-03-25

Similar Documents

Publication Publication Date Title
AR114544A1 (es) Proteínas de unión multiespecíficas que unen a bcma, nkg2d y cd16, y métodos de uso
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
AR117727A1 (es) Anticuerpos que se unen a cd3
EA202091977A1 (ru) Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
MX2020008795A (es) Anti cuerpos anti tigit y usos de los mismos.
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
CO2020010345A2 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
BR112018011336A2 (pt) anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer
PE20210375A1 (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
EA202091976A1 (ru) Вариабельные домены антител, нацеленные на cd33, и их применение
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
EA202092306A1 (ru) Анти-cd24 композиции и их применения
EA202090718A1 (ru) Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
AR108779A1 (es) Anticuerpos
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos